{
    "clinical_study": {
        "@rank": "55198", 
        "arm_group": [
            {
                "arm_group_label": "Drop A", 
                "arm_group_type": "Experimental", 
                "description": "Systane Balance Eye Drops, one drop in the right eye and one drop in the left eye four times a day for 30 days"
            }, 
            {
                "arm_group_label": "Drop B", 
                "arm_group_type": "Active Comparator", 
                "description": "Systane Gel Drops, one drop in the right eye and one drop in the left eye four times a day for 30 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the ability of Systane Balance dosed four times a\n      day for 30 days to improve comfort over baseline compared to Systane gel."
        }, 
        "brief_title": "Systane Balance - Inflammatory Markers", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Dry Eye Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Read, sign, and date the Informed Consent Document;\n\n          -  Willing and able to follow instructions and maintain the appointment schedule;\n\n          -  Must not have used any topical ocular drops for approximately 24 hours prior to Visit\n             1;\n\n          -  Meet the protocol-specified dry eye criteria at Screening Visit (Visit 1);\n\n          -  Willing to use study drugs 4 times per day in both eyes;\n\n          -  Willing to discontinue use of other artificial tear products and other eyedrops;\n\n          -  Intraocular pressure less than or equal to 22 mmHg in both eyes;\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  History or evidence of ocular or intraocular surgery or serious trauma in either eye\n             within the past six months;\n\n          -  Current punctal occlusion of any type (e.g., collagen plugs, silicone plugs);\n\n          -  History of intolerance or hypersensitivity to any component of the study medications;\n\n          -  History or evidence of epithelial herpes simplex keratitis (dendritic keratitis);\n             vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva;\n             chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids;\n             mycobacterial infection of the eye; and/or fungal disease of the eye;\n\n          -  Use of any concomitant topical ocular medications during the study period;\n\n          -  Currently using Restasis and unwilling to discontinue its use 1 month prior to\n             screening and for the entire study period;\n\n          -  Use of systemic medications that may contribute to dry eye unless on a stable dosing\n             regimen for a minimum of 30 days prior to Visit 1;\n\n          -  Uncontrolled ocular conditions such as uveitis, glaucoma or any other ocular\n             condition that may preclude the safe administration of either drop under\n             investigation;\n\n          -  Unwilling to discontinue contact lens wear during the study period and for at least\n             one week prior to Visit 1;\n\n          -  Participation in an investigational drug or device study within 30 days of entering\n             this study;\n\n          -  Pregnant or lactating women;\n\n          -  Monocular or legally blind;\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733732", 
            "org_study_id": "A00976"
        }, 
        "intervention": [
            {
                "arm_group_label": "Drop A", 
                "intervention_name": "Systane Balance Eye Drops", 
                "intervention_type": "Other", 
                "other_name": "SYSTANE\u00ae BALANCE"
            }, 
            {
                "arm_group_label": "Drop B", 
                "intervention_name": "Systane Gel Drops", 
                "intervention_type": "Other", 
                "other_name": "SYSTANE\u00ae Gel Drops"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tetrahydrozoline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dry eye", 
            "Lipid deficiency"
        ], 
        "lastchanged_date": "November 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study to Evaluate the Efficacy of Systane Balance in Reducing Symptoms and Inflammatory Biomarker Expression of HLA-DR and Tear Film Cytokines in Dry Eye Subjects With Lipid Deficiency", 
        "overall_official": [
            {
                "affiliation": "Alcon Research", 
                "last_name": "Abayomi Ogundele, PharmD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Mount Sinai School of Medicine", 
                "last_name": "Penny A. Asbell, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire will be administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The Baseline (Day 0) OSDI score will be subtracted from the Day 30 OSDI score and reported as change. A negative number will represent a perceived improvement in ocular health.", 
            "measure": "Mean Change from Baseline in Ocular Surface Disease Index (OSDI) Score at Day 30", 
            "safety_issue": "No", 
            "time_frame": "Baseline (Day 0), Day 30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733732"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}